This content is in French.
Xeligekimab in moderate to severe plaque psoriasis
21 février 2024
In this study of 420 Chinese patients, researchers evaluated the efficacy and safety of xeligekimab in moderate to severe plaque psoriasis. Xaligekimab is a selective IL-17 inhibitor…
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Lin Cai et al. A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2024 Feb 15:ljae062.
View the source
